Skip to main content

Drug Interactions between pralidoxime and succinylcholine

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

succinylcholine pralidoxime

Applies to: succinylcholine and pralidoxime

MONITOR: Oximes used in organophosphorous poisoning such as pralidoxime or obidoxime may antagonize the neuromuscular blocking effects of succinylcholine and mivacurium. Oximes reactivate acetylcholinesterase that has been inactivated by phosphorylation due to exposure to an organophosphorous nerve agent or insecticide, and the reactivated acetylcholinesterase then hydrolyzes excess acetylcholine resulting from the exposure to help restore impaired cholinergic neural function. Since succinylcholine and mivacurium are metabolized by plasma cholinesterases, patients with organophosphorous poisoning who have been treated with an oxime may exhibit accelerated reversal of the neuromuscular blocking effects of these agents relative to those who have not received an oxime.

MANAGEMENT: Neuromuscular effects should be monitored when succinylcholine or mivacurium is coadministered with an oxime.

References (2)
  1. Selden BS, Curry SC (1987) "Prolonged succinylcholine-induced paralysis in organophosphate insecticide poisoning." Ann Emerg Med, 16, p. 215-7
  2. (2010) "Product Information. DuoDote (atropine-pralidoxime)." Meridian Medical Technologies Inc

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer